Article

Successful phase 2 trial, Aerie Pharmaceuticals, Inc.’s dry eye candidate advancing to phase 3

Author(s):

David Hutton

David Wirta, MD, Medical Director for the Eye Research Foundation, Inc., presents the data of Aerie Pharmaceuticals, Inc.’s novel dry eye product candidate, AR-15512 (0.003%). The successful phase 2 results has propelled the product into phase 3 trials.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
Related Content
FDA clears Grifols' Investigational New Drug application for immunoglobulin drops for the treatment of DED
May 22nd 2025

FDA clears Grifols' Investigational New Drug application for immunoglobulin drops for the treatment of DED

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Q&A: Kapil Mishra on radiation retinopathy in uveal melanoma
May 21st 2025

Q&A: Kapil Mishra on radiation retinopathy in uveal melanoma

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

(Photo courtesy of Malvina Eydelman, MD)
May 18th 2025

Q&A: Malvina Eydelman, MD, on leading CCOI and catalyzing global ophthalmic innovation

(Image credit: AdobeStock/peshkova)
May 17th 2025

Q&A: Joaquin De Rojas, MD, on ASCRS 2025 Best Paper of Session for advancing AK with machine learning

© 2025 MJH Life Sciences

All rights reserved.